SAN DIEGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will participate in the H.C. Wainwright @ Home Event on Wednesday, October 15 th , 2025. Conference & Webcast Details Date: October 15, 2025 Time: 10:00 a.m. to 11:00 a.m. ET Presenter: Erik Holmlin, PhD, CEO of Bionano Webcast: Link to Register A replay /... Read More

SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) (“Bionano” or the “Company”) today announced the closing of its previously announced public offering of an aggregate of 5,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof), Series E warrants to purchase up to 5,000,000 shares of the Company’s common stock and short-term Series F warrants to purchase up... Read More

SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) (“Bionano” or the “Company”) today announced the pricing of a public offering of an aggregate of 5,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof), Series E warrants to purchase up to 5,000,000 shares of the Company’s common stock and short-term Series F warrants to purchase up to 5,000,000 shares of... Read More

SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that an issue of the book series Methods in Molecular Biology dedicated to studies of the catastrophic genome rearrangement known as chromoanagenesis was published with multiple studies highlighting the advantages of optical genome mapping (OGM) in chromoanagenesis research. According to research, chromoanagenesis refers to a... Read More

SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced that Centers for Medicare & Medicaid Services (CMS) posted the preliminary payment determination for the Category I Current Procedural Terminology (CPT®) code for use of OGM in... Read More

SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the H.C. Wainwright 27 th Annual Global Investment Conference on Monday, September 8 th , 2025. Conference & Webcast Details Date: September 8, 2025 Time: 3:00 p.m. to 3:30 p.m. ET Presenter: Erik Holmlin, PhD, CEO of Bionano Webcast: Link... Read More

Conference call today, August 14, 2025, at 4:30 PM ET SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarter ended June 30, 2025. “We continued to execute on our new strategy of focusing on our base of routine users of optical genome mapping (OGM) and VIA™ software as the primary drivers of our revenue and gross profit in the second quarter.... Read More

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication from a team led by Manon Delafoy from the Institut Necker Enfants Malades (INEM) and colleagues from multiple French pediatric hematology centers showing how optical genome mapping (OGM) can be used to detect oncogenic structural variants (SVs) in clinical research of infant and toddler T-cell acute... Read More

SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the Canaccord Genuity 45 th Annual Growth Conference on August 13, 2025. Conference & Webcast Details Date: August 13, 2025 Time: 3:00 p.m. to 3:25 p.m. ET Presenter: Erik Holmlin, PhD, CEO of Bionano Webcast: Link to Register A replay /... Read More

VIA™ 7.2 transforms the workflow for optical genome mapping (OGM) data analysis with AI in constitutional genetic disorders VIA 7.2 supercharges the OGM heme workflow by allowing AI to utilize a lab’s historical results to speed future interpretations VIA 7.2 extends significance associated with phenotype (SAP) scoring to OGM data for the first time and uses that score to help streamline interpretation decisions for OGM... Read More

SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Thursday, August 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date: Thursday, August 14 th , 2025 Time: 4:30 p.m. ET Participant Link: Registration... Read More

SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) recently participated in the European Cytogenomics Conference, which is the biennial meeting of the European Cytogenomics Association (ECA). The conference was held in Leuven, Belgium, from June 29 – July 1 and attracted leading scientists, clinicians, cytogeneticists and laboratory directors from across Europe and the Middle East. Key... Read More

SAN DIEGO, June 18, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) recently participated in the European Society of Human Genetics (ESHG) conference held in Milan, Italy, from May 24-27, 2025. The event highlighted the use of optical genome mapping (OGM) in genetic disease research, with numerous presentations and posters emphasizing its utility in detecting structural variants (SVs) associated with genetic... Read More

Conference call today, May 14, 2025, at 4:30 PM ET SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2025. “The first quarter of 2025 represents the first full quarter of execution after shifting strategy towards a focus on our base of routine users of optical genome mapping (OGM) and VIA™ software as the primary drivers of... Read More

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc . (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date: Wednesday, May 14 th , 2025 Time: 4:30 p.m. ET Participant Link: Registration –... Read More

SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc . (Nasdaq: BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced the publication in the American Journal of Hematology of expert recommendations from the International Consortium for Optical Genome Mapping (ICOGM) for the integration of OGM as... Read More

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication in Genome Research demonstrating that optical genome Mapping (OGM) can be an accurate, cost-effective method for detecting and sizing large repeat expansions, which are a class of structural variation (SV) linked to as many as 40 genetic disorders. Led by Alexander Hoischen and researchers at... Read More

SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a study published in The Journal of Molecular Diagnostics that describes a method for analysis of multiple myeloma (MM) by optical genome mapping (OGM). MM is one of the most common blood cancers, or hematologic malignancies, and is understood to be a difficult sample to analyze using traditional cytogenetics. Direct analysis... Read More

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2024 and revenue outlook for 2025. “2024 has been an important year for Bionano. Despite a challenging external environment with shrinking capital budgets, financial uncertainty for our customers and difficult equity capital markets, we have continued... Read More

SAN DIEGO, and GREENWOOD, S.C., March 24, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) and Greenwood Genetic Center (GGC) today announced a publication in Genome Research describing the first study to use optical genome mapping (OGM) to investigate the genetic landscape of neural tube defects (NTDs). NTDs are the most common birth defect of the central nervous system and some of the most devastating... Read More

Featured Scientific Session: "Evolution of Cytogenomic Technology: Real-World Applications of Optical Genome Mapping in the Laboratory", an accredited continuing medical education (CME) session, with a panel of experts presenting research on OGM's clinical and translational applications. Dr. Adam Smith (University of Toronto, Canada; currently at Labcorp, USA) will provide an overview of OGM’s evolution into an essential... Read More

SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Monday, March 31, 2025, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date: Monday, March 31 st , 2025 Time: 4:30 p.m. ET Participant Link:... Read More

In-Motion Webinar: Bionano will host a webinar featuring the study’s lead author, Dr. Guilin Tang, who will discuss the study and its findings in detail, including a summary of the potential implications for wide-spread adoption of optical genome mapping Time and Date: April 15, 2025 at 9:30 AM Central Time, USA Registration details to be made available at Bionano.com SAN DIEGO, March 13, 2025 (GLOBE NEWSWIRE) -- Bionano... Read More

SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO)(the “Company”) today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-60. The effective time of the reverse stock split will be 5 p.m. ET on January 24, 2025. The Company’s common stock will begin trading on a split-adjusted basis commencing upon market open on January 27,... Read More

OGM uniquely identified a complex chromosomal rearrangement missed by classical cytogenetics, helping clinical researchers apply targeted screening to select the most fit embryos for transfer Following in-vitro fertilization, preimplantation genetic testing and selection of fit embryos, a healthy baby was born to a couple that had previously experienced years of recurrent pregnancy loss SAN DIEGO, Jan. 14, 2025 (GLOBE... Read More

Preliminary Q4 2024 revenue expected to be between $7.9 and $8.1 million, which would represent an estimated decrease of approximately 25% over Q4 2023 due primarily to discontinuation of clinical service products in 2024 Installed base of optical genome mapping (OGM) systems reached an estimated 371 as of YE 2024, which is an increase of 14% over the 326 installed OGM systems as of YE 2023 Preliminary number of nanochannel... Read More

A case study published by researchers at Johns Hopkins University showed that optical genome mapping (OGM) detected a structural variant that was missed by karyotyping and non-informative by FISH, which they classified as a PML::RARA fusion known to occur in acute promyelocytic leukemia (APL) The researchers reported that APL, an aggressive subtype of acute myelogenous leukemia (AML), responds well to treatment with... Read More

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 39,682,540 shares of its common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 39,682,540 shares of common stock (the “Warrants”), at a... Read More

SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 39,682,540 shares of its common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 39,682,540 shares of common stock (the “Warrants”), at a combined offering price of... Read More

SAN DIEGO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a settlement agreement and amendment to its outstanding senior secured convertible debentures due May 26, 2024 (the “Amendment”). Importantly the Amendment defers the Company’s December 2024 amortization payment and reduces the payments due in January 2025 through July 2025 from $1,000,000 per month to... Read More

In the largest study to date of bone and soft tissue tumors, OGM detected 100% of the variants found by multiple standard techniques, including karyotyping, fluorescent in-situ hybridization (FISH) & gene fusion assays OGM was also more sensitive, including detection of diagnostic or pathogenic variants missed by karyotype in 74% (14/19) of cases that failed or were negative by karyotyping When OGM results and... Read More

SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced that on December 19, 2024, it published an open letter to stockholders in support of its proposals at its upcoming special meeting of stockholders, a copy of which is included at the end of this press release. Details of the Special Meeting of Stockholders The special meeting of stockholders will be held virtually, via live webcast at... Read More

Thirteen scientific posters feature results from OGM applications in myeloid cancers, acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), lymphoma, and other hematological malignancy research will be presented at the conference Three of the 13 posters were selected to be presented in two sessions dedicated to “Acute Myeloid Leukemias (AML): Biomarkers and Molecular Markers in Diagnosis and Prognosis” and... Read More

Q3 2024 revenue was $6.1 million, which comprises $6.6 million in core product and software sales which is offset by $0.5 million because of a write-down of aged receivables tied to discontinued clinical service products. Q3 2024 revenue represents a 35% decrease from Q3 2023 Total installed base of 368 optical genome mapping (OGM) systems as of Q3 2024, which represents a 22% increase over Q3 2023 Sold 7,835 nanochannel... Read More

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 13, 2024, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date: Wednesday, November 13th, 2024 Time: 4:30 p.m. ET Participant Link:... Read More

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-marker under Nasdaq rules for the purchase and sale of an aggregate of 9,881,113 shares of its common stock and Series C warrants to purchase up to an aggregate of 9,881,113 shares of common stock and short-term Series D warrants to purchase up to... Read More

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 9,881,113 shares of its common stock and Series C warrants to purchase up to an aggregate of 9,881,113 shares of common stock and short-term Series D warrants to purchase up to an aggregate of... Read More

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that it adjourned its reconvened Special Meeting of Stockholders originally held on October 2, 2024 and subsequently adjourned to October 30, 2024 (the “Special Meeting”) because a quorum was not present at the time of the reconvened meeting. Based on preliminary reports as of October 30, 2024, approximately 30.7% of total... Read More

Publication shows that OGM can resolve translocation partners involving MYC in multiple myeloma (MM) more effectively than current methods The release of compelling data in MM underscores the potential for wider adoption and use of OGM across all blood cancers as an alternative to traditional methods like karyotyping and fluorescence in-situ hybridization (FISH) SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics,... Read More

SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced select preliminary results for the quarter ended September 30, 2024. The Company now expects revenue for the third quarter of 2024 to be between $6.5 and $6.8 million, down from prior guidance of between $7.9 and $8.9 million. Cash, cash equivalents, available-for-sale securities, and restricted cash were approximately $23.3... Read More

SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that it has adjourned its Special Meeting of Stockholders held on October 2, 2024 (the “Special Meeting”) because a quorum was not present at the time of meeting. Based on preliminary reports as of October 2, 2024, only 22.5% of total shares outstanding as of the record date have submitted their votes, whereas 33.3% of total... Read More

SAN DIEGO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the H.C. Wainwright 26 th Annual Global Investment Conference on Monday, September 9 th , 2024. Conference & Webcast Details Date: September 9, 2024 Time: 11:00 a.m. to 11:30 a.m. ET Presenter: Erik Holmlin, PhD, CEO of Bionano Webcast:... Read More

Q2 2024 revenue was $7.8 million, which represents a 10% decrease from Q2 2023 Total installed base of 363 optical genome mapping (OGM) systems as of Q2 2024, which represents a 29% increase over Q2 2023 Sold 6,165 nanochannel array flowcells in Q2 2024, which represents a 13% decrease from the number of flowcells sold in Q2 2023 The editorial panel of the American Medical Association (AMA) established a new Category I... Read More

A sponsored exhibitor session will feature Dr. Phillip Michaels from Harvard Medical School and Brigham and Women’s Hospital presenting data from a multi-site study evaluating the performance and benefits of optical genome mapping (OGM) in comparison to classical methods for hematological malignancies Two scientific poster presentations from researchers at Vancouver General Hospital and Dartmouth Hitchcock Medical Center... Read More

SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the Canaccord Genuity 44 th Annual Growth Conference on August 13, 2024. Conference & Webcast Details Date: August 13, 2024 Time: 3:30 p.m. to 3:55 p.m. ET Presenter: Erik Holmlin, PhD, CEO of Bionano Webcast: Link to Register A replay /... Read More

SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, August 7, 2024, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date: Wednesday, August 7th, 2024 Time: 4:30 p.m. ET Participant Link: Registration –... Read More

SAN DIEGO, July 23, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of the first multi-site study in multiple myeloma (MM) comparing optical genome mapping (OGM) to traditional cytogenetic methods for the detection of structural variants (SVs). Multiple myeloma is a type of blood cancer originating in the plasma cell, known as a plasma cell neoplasm (PCN), and though sensitive... Read More

SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 17,513,136 shares of its common stock (or common stock equivalents in lieu thereof) at an offering price of $0.571 per share of common stock (or per common stock equivalent in... Read More

SAN DIEGO, July 05, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the purchase and sale of an aggregate of 17,513,136 shares of its common stock (or common stock equivalents in lieu thereof) at an offering price of $0.571 per share of common stock (or per common stock equivalent in lieu... Read More

A sponsored session will feature Dr. Lucia Gallego Villarejo from Ruhr University Bochum, Dr. Jeanne Loring from Scripps Research Institute, and Dr. Alicia Bertolotti from Bionano presenting on the utility of optical genome mapping (OGM) across cell and gene therapy research, development and manufacturing applications Two scientific posters featuring results from OGM applications in cell manufacturing and bioprocessing... Read More

Bionano has entered into a software marketing agreement with Revvity, Inc. (Revvity) under which Revvity will market and commercialize Bionano’s VIA™ software to Revvity’s next generation sequencing (NGS) customers as part of its newborn sequencing research workflow VIA is expected to enhance Revvity’s newborn sequencing solution by adding an assessment of copy number variation (CNV) to the NGS solution report and... Read More

SAN DIEGO, June 17, 2024 (GLOBE NEWSWIRE) -- Bionano Laboratories , a clinical laboratory services business of Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of optical genome mapping (OGM) in cytogenomic genome-wide analysis to detect structural and copy number variations... Read More

A record 31 scientific presentations and posters at the 2024 European Society for Human Genetics (ESHG) Annual Conference and 8 scientific presentations and posters at the 2024 American Cytogenomics Conference (ACC) will highlight the application of optical genome mapping (OGM) in genetic disorder, rare disease, and cancer research applications Bionano will host a sponsored session at ESHG featuring an overview of the... Read More

SAN DIEGO, May 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics Inc. (“Bionano” or the “Company”) (NASDAQ: BNGO) today announced that it has completed a private placement of senior secured convertible debentures due May 24, 2026. The Company received gross proceeds of $18.0 million in connection with the placement, which will allow the Company to completely retire the convertible debt financing previously entered into first in... Read More

Three peer-reviewed publications collectively illustrate the building support for optical genome mapping (OGM) as a tool for cell and gene therapy development that allows researchers in academic medical centers and biopharmaceutical companies to assess genome integrity in therapeutic cell lines like chimeric antigen receptor-modified T cells (CAR-T), stem cells, and cell lines used for translational research in unraveling... Read More

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced significant upgrades to its suite of computational tools for comprehensive cancer analysis. These advancements to the company’s VIA™ software solution enhance the detection and interpretation of aneusomies, and improve the analysis, visualization, interpretation, and reporting of data types including optical genome mapping... Read More

Q1 2024 revenue was $8.8 million, which represents an 18% increase over Q1 2023 Total installed base of 347 optical genome mapping (OGM) systems as of Q1 2024, which represents a 34% increase over Q1 2023 Sold 8,249 nanochannel array flowcells in Q1 2024, which represents a 58% increase over the number of flowcells sold in Q1 2023 Efforts to reduce cash burn and operating expense continued with the March 2024 announcement of... Read More

SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date: Wednesday, May 8th, 2024 Time: 4:30 p.m. ET Participant Dial-In: Toll Free:... Read More

SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the RBC Capital Markets 2024 Global Healthcare Conference on May 15, 2024. Conference & Webcast Details Date: May 15, 2024 Time: 8:00 a.m. to 8:25 a.m. ET Presenter: Erik Holmlin, PhD, CEO of Bionano Webcast: Link to Register A replay /... Read More

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the results of an implementation study conducted by researchers at University Medical Center Groningen that compared optical genome mapping (OGM) to traditional cytogenetic methods for the detection of structural variants (SVs) in bone marrow aspirate (BMA) samples. OGM has been shown to regularly detect SVs missed by other... Read More

Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology. Their joint endeavor aims to commercialize the first ever cytogenetic workflow that integrates OGM plus AI chromosome... Read More

SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study from Penn State College of Medicine that used optical genome mapping (OGM) to search for clinically and biologically relevant genomic variations in pediatric B-cell acute lymphoblastic leukemia (B-ALL). The study also used whole genome sequencing (WGS) for variant detection and evaluated the two... Read More

SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 8,733,626 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 8,733,626 shares of its common stock at an offering price of $1.145 per share of common stock (or per... Read More

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a peer-reviewed study that compared optical genome mapping (OGM) to classical cytogenetic techniques used for analysis of solid tumor cancer samples consisting of soft tissue and bone sarcomas, including fluorescence in situ hybridization (FISH) and karyotyping (KT). OGM demonstrated high levels of... Read More

Nine scientific posters will illustrate the application of optical genome mapping (OGM) in cancer research areas including hematological malignancies, solid tumors, and applications in cell and gene therapy, cell manufacturing and bioprocessing quality control Bionano is introducing its new Stratys™ system for high throughput OGM to the cancer research community Bionano will preview VIA™ 7.1 software, an upcoming advancement... Read More

SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study of optical genome mapping (OGM) in hereditary breast and ovarian cancer (HBOC) syndrome showing that when tumors exhibited higher overall numbers of structural variations (SVs) they tended to have more mutated genes and altered signaling pathways, which may correlate with poor prognosis, tumor... Read More

Bionano will host a pre-conference scientific session that will include a live product demonstration of the Stratys™ system for high throughput optical genome mapping (OGM) and findings from early access customers The pre-conference event will also include a 2024 corporate overview from Bionano’s chief executive officer, Dr. Erik Holmlin, presentations from Dr. Brynn Levy at Columbia University Medical Center, Dr. Ulrich... Read More

Q4 2023 revenue was $10.7 million, which represents a 30% increase over Q4 2022 FY 2023 revenue was $36.1 million, which represents a 30% increase over FY 2022 Reached installed base of 326 optical genome mapping (OGM) systems as of YE 2023; increase of 36% over the 240 installed systems as of YE 2022 Sold 26,444 nanochannel array flowcells in FY 2023, which represents a 72% increase over the flowcells sold in FY 2022... Read More

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at TD Cowen’s 44 th Annual Health Care Conference on March 6, 2024. Conference & Webcast Details Date: Wednesday, March 6th, 2024 Time: 12:50 p.m. to 1:20 p.m. ET Presenter: Erik Holmlin, PhD, CEO of Bionano Webcast: Link to Register A replay... Read More

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc . (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 5, 2024, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2023 and to highlight recent corporate progress. Conference Call & Webcast Details Date: Tuesday, March 5th, 2024 Time: 4:30 p.m. ET Participant Call Link:... Read More

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (“Bionano”) (Nasdaq: BNGO) today announced that is has amended the convertible debt financing the company entered into in October 2023 pursuant to which the company agreed to issue and sell to a certain accredited investor (the “Buyer”) (i) in a registered offering by the company (a) $45.0 million aggregate principal amount of senior secured convertible... Read More

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical genome mapping (OGM) was included for the first time in the American College of Medical Genetics and Genomics (ACMG) technical laboratory standards documentation for solid tumor analysis. The section, which was last updated in 2016, includes an overview of current cytogenomic techniques for solid tumor analysis... Read More

SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will take place February 13-14, 2024. Please contact your BTIG representative if you would like to schedule a virtual or in-person meeting with... Read More

Over 2,100 registrants with attendees from 92 countries Average daily attendance of 574 32 oral presentations delivered across four consecutive days 69 scientific posters featuring optical genome mapping (OGM) on view in the online exhibit hall Content covered wide a range of research applications for OGM including hematologic malignancies, cell and gene therapy, and constitutional genetic diseases On-demand presentations... Read More

SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication in Cancers from a team of cancer researchers primarily at the NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute and Scripps MD Anderson in La Jolla, California. The publication describes what could be the first study to use optical genome mapping (OGM) for the discovery... Read More

Pre-print publication from Levy, et al. describes the second phase of a multisite evaluation and validation of optical genome mapping (OGM) that is designed to measure the workflow’s accuracy and clinical utility compared to classical cytogenetic methods OGM data from 342 unique cases (419 datapoints) were analyzed and reported in the pre-print, including 123 samples from phase 1 of the study, which was reported in a... Read More

Bionano has completed the early access program for the Stratys™ system and is now making it available in a full commercial release The Stratys instrument can enable up to a four-fold increase in raw data generation rate compared to the Saphyr® instrument and can process up to 12 single access chips , accessible as they complete runs, without the need to batch multiple samples on a consumable Data analysis for the Stratys... Read More

26 different customers representing North America, Asia and Europe 33 oral presentations across four consecutive days 69 scientific posters will be featured in a virtual exhibition hall Topics span the application of optical genome mapping (OGM) in research applications in cancer, cell and gene therapy, and genetic diseases SAN DIEGO, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc (Nasdaq: BNGO) today announced its... Read More

Peer-reviewed publication from Broeckel, et al. describes the second phase of a multisite evaluation of optical genome mapping (OGM) in 627 samples (597 unique samples and 30 replicates) Overall, for the entire study, OGM data have been collected from 1,000 samples, including 404 samples from phase 1 of the study Concordance for pathogenic variants in all combined samples against standard of care (SOC) methods – 99.5% (995... Read More

SAN DIEGO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its 2024 Symposium, the quintessential event for the optical genome mapping (OGM) community. The event is an opportunity for OGM users to present their progress to the world. 2024 Symposium will feature four consecutive days of OGM presentations delivered by 27 different customers worldwide across a wide range of applications... Read More

Preliminary Q4 2023 revenue expected to be between $10.4 and $10.7 million, which would represent an estimated increase of 27% to 30% over Q4 2022 Reached installed base of 326 optical genome mapping (OGM) systems as of YE 2023; increase of 36% over the 240 installed systems as of YE 2022 Preliminary number of nanochannel array flowcells sold in Q4 2023 expected to be 7,980, which would represent an estimated increase of 67%... Read More

SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced a publication outlining the addition of optical genome mapping (OGM) to the International System for Human Cytogenomic Nomenclature (ISCN). The OGM nomenclature is expected to be published in the 2024 edition of the ISCN guide, a reference volume covering ISCN nomenclature that is utilized worldwide by cytogeneticists,... Read More

Framework was co-authored by an international consortium made up of 18 cancer researchers Publication includes researchers’ recommendations for laboratories planning to adopt optical genome mapping (OGM) on topics including assay development, clinical validation, implementation, algorithms for data interpretation, and strategies for efficient reporting Bionano Laboratories developed its laboratory developed test (LDT),... Read More

SAN DIEGO, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced significant upgrades to its pipeline for analysis of optical genome mapping (OGM) data in its VIA™ software for applications in constitutional genetic disease. The latest analysis pipeline, Bionano Solve 3.8.1, enhances the sensitivity and specificity for structural variation (SV) detection from OGM data, which, when combined... Read More

Key findings from prospective evaluation of 200 prenatal samples: Optical genome mapping (OGM) detected pathogenic structural variants (SVs) in 20.5% of samples (41/200); combination of chromosomal microarray analysis (CMA) and karyotyping (KT) detected pathogenic SVs in 19.5% of samples (39/200) Compared to CMA and KT combined in this prospective cohort, OGM had the following performance: Sensitivity: 97.4% Specificity:... Read More

SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a special issue of Cancers journal entirely dedicated to the Company’s optical genome mapping (OGM) workflow. The issue, which features guest editors Dr. Adam Smith from University of Toronto, Dr. Gordana Raca from Children’s Hospital Los Angeles, and Dr. Alexander Hoischen from Radboud University Medical... Read More

SAN DIEGO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication of a study covering the analytical validation of its laboratory developed test (LDT), marketed as OGM-Dx™ HemeOne. This LDT is based on optical genome mapping (OGM) analysis of blood or bone marrow samples to detect structural variants (SVs) of diagnostic and prognostic utility in individuals with a new or an existing diagnosis... Read More

A platform presentation will feature Dr. Enze Liu from the Indiana University School of Medicine sharing findings from a study on the use of optical genome mapping (OGM) to detect structural variants (SVs) in multiple myeloma Thirteen scientific posters featuring results from OGM applications in myeloid cancers, acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS) and hematological malignancy research will be... Read More

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication by scientists at Revvity Omics (formerly Perkin Elmer Genomics), Leiden University Medical Centre, Bombay Hospital, and UT Dallas, of the largest peer-reviewed study to date on the use of optical genome mapping (OGM) to diagnose facioscapulohumeral muscular dystrophy (FSHD). The publication describes the evaluation of an... Read More

SAN DIEGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication demonstrating the use of optical genome mapping (OGM) to identify structural variations (SVs) introduced by CRISPR-Cas9 gene editing of CD4+ T-cells that could potentially limit the therapeutic use of such edited cells. The research study authors used OGM in combination with drop-off digital PCR (ddPCR) to assess... Read More

QUEBEC CITY, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- LeddarTech ® , an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, proudly announces the appointment of Mr. Chris Stewart as Chief Financial Officer (“CFO”). As CFO at LeddarTech, Mr. Stewart will be instrumental in supporting LeddarTech in completing its recently announced business... Read More

A corporate workshop session will feature Dr. Alka Chaubey, Bionano’s chief medical officer, Dr. Panieh Terraf from Memorial Sloan Kettering Cancer Center, Dr. Ravindra Kolhe from Augusta University, and Dr. Miriam Bornhorst from Children’s National Hospital presenting data on the role of structural variants (SVs) in central nervous system (CNS) tumor analysis conducted using optical genome mapping (OGM) A second corporate... Read More

Q3 2023 revenue was $9.3 million, which represents a 29% increase over Q3 2022 Installed base of Saphyr ® systems totaled 301 as of September 30, 2023, which represents a 39% increase over the number of systems installed as of September 30, 2022 Sold 6,176 nanochannel array flowcells in Q3 2023, which represents a 55% increase over the number of flowcells sold in Q3 2022 Completed an $80.0 million registered offering and... Read More

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical genome mapping (OGM) was included for the first time in Thompson and Thompson Genetics and Genomics in Medicine , 9 th edition, a textbook regularly used for medical students, genetic counseling students, students in laboratory medicine, and more advanced trainees pursuing American Board of Medical Genetics and... Read More

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at 2023 Stifel Healthcare Conference on November 15, 2023. Conference & Webcast Details Date: Wednesday, November 15th, 2023 Time: 1:50 p.m. to 2:20 p.m. ET Presenter: Erik Holmlin, PhD, CEO of Bionano Webcast: Link to Register A replay /... Read More

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2023 and to highlight recent corporate progress. Conference Call & Webcast Details Date: Wednesday, November 8th, 2023 Time: 4:30 p.m. ET Participant Call Link:... Read More

A sponsored session will feature Dr. Brynn Levy from Columbia University Medical Center, Dr. Roger Stevenson, founder of Greenwood Genetic Center, and Dr. Alex Hastie from Bionano presenting on the utility of optical genome mapping (OGM) across constitutional genetics research applications An industry co-lab session led by Dr. Sam Dougaparsad from Bionano will provide attendees with an overview of Bionano’s end-to-end OGM... Read More

Bionano announced today that it has priced a financing to raise an aggregate of $80.0 million in a registered offering and concurrent private placement of senior secured convertible notes due 2025 and warrants Preliminary Q3 revenue expected to be between $9.1 and $9.3 million, which would represent an estimated increase of 26% to 29% over Q3 2022 and would be at the higher end of revenue guidance of $8.8 million to $9.2... Read More

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of senior secured convertible notes due 2025 (the “Registered Notes”) and warrants (the “Registered Warrants”) to purchase 21,660,650 shares of its common stock in a registered offering, and (ii) $35.0 million aggregate principal amount of senior secured convertible... Read More

SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first peer-reviewed benchmarking study to compare optical genome mapping (OGM) to the current global standard in molecular analysis of constitutional genetic disorders, chromosomal microarray analysis (CMA). The study evaluated the potential of OGM to measure all classes of variant types covered by CMA,... Read More

SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that on September 18, 2023, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted an inducement award consisting of a non-qualified stock option to purchase 106,000 shares of common stock to Gülsen Kama, the Company’s new Chief Financial Officer, under the Company’s 2020... Read More

Bionano original equipment manufacturing (OEM) partner Ecobono obtained reagent Class I registration and approval for Bionano’s DNA isolation kits for optical genome mapping (OGM) from China's National Medical Products Administration (NMPA) Reagents can be utilized for in vitro diagnostics (IVD) use in China With this NMPA registration, Ecobono can sell OGM reagents to independent clinical laboratories and Chinese hospitals... Read More

SAN DIEGO, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a study detailing the challenges associated with the detection and interpretation of causal variants in Mendelian disease, using a cohort of 4,577 families. The study authors conducted a comprehensive analysis of samples from the cohort in which non-sequencing-based challenges were encountered, and then... Read More

SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication from researchers at the German Cancer Consortium (DKTK) showing the utility of optical genome mapping (OGM) and whole-exome sequencing (WES) in better understanding the mutational landscape of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Researchers compared the analysis of 60... Read More

SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication in Nature Communications demonstrating the utility of optical genome mapping (OGM) as an alternative to karyotyping (KT) and chromosomal microarray (CMA) for the evaluation of CRISPR-Cas9 edited human induced pluripotent stem cell (iPSC) lines in order to uncover possible pathogenic structural alterations that may... Read More

Bionano original equipment manufacturing (OEM) partner A-smart MedTech (A-smart) obtained reagent class I registration and approval for DNA isolation and labeling kits for optical genome mapping (OGM) from China's National Medical Products Administration (NMPA) Reagents can be utilized for in vitro diagnostics (IVD) use in reproductive health in China With this NMPA registration, A-smart can sell OGM reagents to independent... Read More

SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has received a letter from the staff of the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with Nasdaq's minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the... Read More

SAN DIEGO, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories , a laboratory services business of Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that it has received Laboratory Accreditation from the College of American Pathologists (CAP) for its Clinical Laboratory Improvement Amendments (CLIA)-certified reference lab. CAP accreditation is awarded to laboratories that meet stringent requirements and maintain the... Read More

SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role. Ms. Kama has an extensive background in business planning and execution, especially... Read More

Dr. Alka Chaubey, chief medical officer at Bionano, will host a sponsored vendor panel presentation on the integration of OGM for clinical research in cancer, featuring cancer genomics experts Dr. Ravindra Kolhe, Augusta University, Dr. Yassmine Akkari, Nationwide Children’s Hospital, Dr. Susan Crocker, Kingston Health Sciences Centre/ Queen’s University, and Dr. Sachin Jadhav, HCG Network Thirteen scientific platform and... Read More

Q2 2023 revenue was $8.7 million, which represents a 30% increase over Q2 2022 Installed base of Saphyr ® systems totaled 281 as of June 30, 2023, which represents a 43% increase over Q2 2022 Sold 7,062 nanochannel array flowcells as of June 30, 2023, which represents a 108% increase over the number of flowcells sold in Q2 2022 Conference call today, August 9 th , 2023, at 4:30 PM ET SAN DIEGO, Aug. 09, 2023 (GLOBE NEWSWIRE)... Read More

SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on August 4, 2023. The Company’s common stock will begin trading on a split-adjusted basis commencing upon market open on August 7, 2023. As... Read More

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, August 9, 2023, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2023 and to highlight recent corporate progress. Conference Call & Webcast Details Date: Wednesday, August 9th, 2023 Time: 4:30 p.m. ET Participant Call Link:... Read More

SAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the successful launch of its optical genome mapping (OGM) roadshow, Bionano TOUR, a series of regional customer-led events that showcase the latest advancements to the OGM workflow and demonstrate applicable research applications. Bionano TOUR provides an immersive in-person experience for attendees, combining informative... Read More

SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, Ph.D., Bionano’s president and chief executive officer will present at the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023. Conference & Webcast Details Date: Thursday, August 10th, 2023 Time: 11:30 a.m. to 11:55 a.m. ET Presenter: Erik Holmlin, Ph.D., CEO of Bionano Webcast:... Read More

The Stratys ™ instrument for optical genome mapping (OGM) will enable a four-fold increase in raw data generation rate compared to the Saphyr ® instrument. Our plan is to eventually enable labs to develop work-cells comprised of multiple Stratys instruments to reach an increase in data generation rates of up to 13-fold over Saphyr. Approximately 10 Stratys instruments will be available as part of an early access program in... Read More

SAN DIEGO, June 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc . (BNGO), today announced that the company will participate at the Healthcare Virtual Conference , presented by Maxim Group LLC and hosted by M-Vest. Erik Holmlin, Ph.D., Bionano’s president and chief executive officer, is scheduled to present a company overview and fire-side chat discussion hosted by Michael Okunewitch, Senior Research Analyst at Maxim Group... Read More

SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced the publication in Cancers of a peer-reviewed study from Augusta University on the utility of combining optical genome mapping (OGM) and a 523-gene next-generation sequencing (NGS) panel for the standard evaluation of myeloid cancers. Medical society guidelines recommend the use of karyotyping (KT), fluorescence in-situ hybridization... Read More

SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its stockholders approved all proposals set forth at its 2023 Annual Meeting, held earlier today. The final voting results will be available in a current report on Form 8-K, which will be filed with the SEC within 4 days of the meeting. “We appreciate the support of our stockholders on these critically important proxy... Read More

A sponsored session will feature Dr. Alex Hastie from Bionano, Dr. Suk See De Ravin from National Institute of Health (NIH) and Travis Hardcastle from Synthego presenting on the utility of optical genome mapping (OGM) across cell and gene therapy research, development and manufacturing applications SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the... Read More

Grand prize winner, Dr. Michael Khodadoust at Stanford University in Palo Alto, California, will use the Saphyr® system for research into CTCL (cutaneous t-cell lymphoma) Runner up prize winners are Dr. Afia Hasnain at The Hospital for Sick Children in Toronto, Canada, who will investigate ALL (acute lymphoblastic leukemia) samples using Children’s Oncology Group protocols, and Dr. Stefan Rentas at Duke University in... Read More

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the company’s robust presence at key European cytogenetic conferences, including the European Hematology Association (EHA) 2023 Congress, the European Human Genetics (ESHG) 2023 Conference and the European Association for Cancer Research (EACR) 2023 Congress. Optical genome mapping (OGM) will be featured in scientific posters... Read More

SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the commercial release of new kits for its Ionic ® Purification System featuring new chemistry for nucleic acid extraction from formalin-fixed paraffin-embedded (FFPE) and tumor tissue. These products offer potential improvements in quality and yield of nucleic acid extracted from complex biological samples including those with... Read More

Q1 2023 revenue was $7.4 million, which represents a 30% increase over Q1 2022 Installed base of 259 Saphyr® systems totaled as of Q1 2023, which represents a 47% increase over Q1 2022 Sold 5,226 nanochannel array flowcells in Q1 2023, which represents a 62% increase over the number of flowcells sold in Q1 2022 Conference call today, May 9, 2023 at 4:30 PM ET SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc.... Read More

SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2023 and to highlight recent corporate progress. Conference Call & Webcast Details Date: Tuesday, May 9th, 2023 Time: 4:30 p.m. ET Live call: Toll-Free: (800) 715-9871... Read More

SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced that on May 1, 2023, it published an open letter to stockholders in support of its proposals at its upcoming annual meeting of stockholders, a copy of which is included at the end of this press release. Details of the Annual Meeting of Stockholders The annual meeting of stockholders will be held virtually, via live webcast at... Read More

Three peer-reviewed publications collectively illustrate the building support in Europe for optical genome mapping (OGM) as a powerful alternative to traditional methods of cytogenetic analysis for hematological malignancies Taken together, the publications, a review paper and two independent studies, illustrate that OGM is not only comparable to traditional methods of cytogenetic analysis for hematological malignancies but... Read More

Preliminary Q1 total revenue expected to be between $7.3 and $7.5 million, which would represent an estimated increase of 28% to 32% over Q1 2022 Installed base of Saphyr® systems reached 259 as of March 31, 2023, which represents growth of the installed base by 19 systems in the quarter and an increase of 47% over the installed base of 176 Saphyr® systems as of March 31, 2022 Preliminary number of nanochannel array... Read More

Preliminary Q1 total revenue expected to be between $7.3 and $7.5 million, which would represent an estimated increase of 28% to 32% over Q1 2022 Installed base of Saphyr® systems reached 259 as of March 31, 2023, which represents growth of the installed base by 19 systems in the quarter and an increase of 47% over the installed base of 176 Saphyr® systems as of March 31, 2022 Preliminary number of nanochannel array... Read More

A sponsored session will feature Dr. Ben Finlay from Sanford Burnham Prebys Institute, Dr. Marc Henri Stern from Institut Curie and Dr. Rashmi Kanagal-Shamanna from MD Anderson Cancer Center presenting on the utility of optical genome mapping (OGM) across cancer therapy research and development applications Five scientific... Read More

SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study from researchers at Radboud University Medical Center showing the use of optical genome mapping (OGM) to identify gene disruptive structural variants (SVs) that might contribute to inherited retinal... Read More

Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome is among several forms of Müllerian agenesis, a disorder impacting 1 in 4,500 females which is indicated by the absence or underdevelopment of the female reproductive system Researchers in the study hypothesized that a genome-wide structural variant (SV) analysis would result in... Read More

SAN DIEGO, March 15, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the expansion of its clinical testing menu with the launch of two new laboratory developed tests (LDTs) based on optical genome mapping (OGM), OGM-Dx TM Postnatal Whole Genome SV and OGM-Dx TM Prenatal Whole Genome SV. These LDTs offer a... Read More

Bionano CEO and president Dr. Erik Holmlin will participate with Dr. Bruce Korf, president of the ACMG Foundation, in the foundation’s educational and clinical laboratory genetics and genomics (LGG) awards ceremony by presenting the fellowship awards sponsored by Bionano A scientific session on innovations in genomics will... Read More

Q4 revenue was $8.2 million, which represents a 30% increase over Q4 2021 2022 revenue was $27.8 million, which represents a 55% increase over year end 2021 Reached installed base of 240 Saphyr® systems as of YE 2022, which represents a 46% increase over YE 2021 Conference call today, March 9 th , 2023 at 4:30 PM ET SAN DIEGO,... Read More

Peer-reviewed publication from Iqbal, et al. describes the multi-site evaluation of optical genome mapping (OGM) for postnatal genetic disorders with 404 samples and shows: Concordance of OGM against various standard of care (SOC) methods –99.5% [399 out of 401 samples] First-pass success rate for OGM – 90.2% [369 out of 409... Read More

SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Thursday, March 9 th , 2023 at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2022 and to highlight recent corporate progress.... Read More

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that company management will present at the 43rd Annual Cowen Healthcare Conference. Erik Holmlin, Ph.D., Bionano’s president and chief executive officer, is scheduled to present a corporate overview on Monday, March 6th, 2023 at... Read More

Bionano original equipment manufacturing (OEM) partner Beijing Genome Precision Technology (BGPT) obtained reagent class I registration and approval for DNA isolation and labeling kits from China's National Medical Products Administration (NMPA) Reagents can be utilized for in vitro diagnostics use in hematologic malignancies... Read More

Bionano leaders presented on the ability of optical genome mapping (OGM) to potentially replace traditional cytogenetic methods for structural variant (SV) detection and shared details of the company’s new product advancements Bionano and NVIDIA previewed their collaborative development, a new compute solution for OGM analysis... Read More

Bionano’s chief executive officer, chief financial officer, chief medical officer, chief operating officer and vice president of clinical and scientific affairs delivered an in-depth review of the company’s strategy, growth drivers, and financial objectives, as well as key initiatives related to clinical trials and new product... Read More

Over 3,000 registrants with attendees from 114 countries Average daily attendance of 750 in 2023 versus 565 in 2022 31 oral presentations delivered across four consecutive days 69 scientific posters featuring optical genome mapping (OGM) on view in the online exhibit hall On-demand presentations from Symposium available for... Read More

SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the launch of OGM-Dx™ HemeOne™, a laboratory developed test (LDT) based on optical genome mapping (OGM) analysis of blood or bone marrow samples to detect structural variants (SVs) of diagnostic and prognostic utility in individuals with a new or... Read More

Bionano Prep SP-G2 (SP-G2) kit offers higher gDNA quality, improved ease-of-use and increased DNA throughput Bionano Prep Direct Label and Stain-G2 (DLS-G2) kit offers increased reagent stability and labeling efficiency resulting in significantly faster sample to results workflow Saphyr Chip® G3.3, instrument control software... Read More

27 different customers representing North America and Europe 30 oral presentations across four consecutive days 34 scientific posters will be featured in a virtual exhibition hall Topics span the application of optical genome mapping (OGM) in genetic disease, cancer research and cell bioprocessing SAN DIEGO, Jan. 20, 2023... Read More

IRB-approved, multi-site, ongoing study evaluated 200 samples representing 123 unique prenatal cases across 9 sites for interim measures of key endpoints: Results of OGM analysis were comparable, in a single assay, to the results of two separate standard of care (SOC) tests needed to reach a diagnosis in 56% of cases (69/123)... Read More

SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a collaboration with NVIDIA to develop an acceleration platform for use in Bionano’s optical genome mapping (OGM) workflow. This collaboration is expected to significantly improve data processing speed while reducing time and... Read More

SAN DIEGO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study analyzing optical genome mapping (OGM) as a method to identify homologous recombination deficiency (HRD) in breast cancer samples. The study reported that OGM successfully assessed levels of HRD in all... Read More

SAN DIEGO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced its 2023 Symposium, which is the quintessential event for the optical genome mapping (OGM) community to present its progress to the world. It will feature four consecutive days of OGM presentations delivered by 25 different customers... Read More

SAN DIEGO, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it will host its first-ever Strategy Day on Thursday, February 2nd, 2023, at the Nasdaq MarketSite in New York City, starting at 1:30 PM ET. The event will include presentations from members of the company's leadership team and... Read More

Preliminary Q4 revenue expected to be between $8.1 and $8.4 million; 29% to 33% increase over Q4 2021 Reached installed base of 240 systems as of YE 2022; 46% increase over YE 2021 Achieved or exceeded all stated goals and milestones for the full year 2022 SAN DIEGO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc.... Read More

Researchers from eight research institutes recommend OGM as first-line analysis for AML due to its ability to perform better and cost less than analysis with karyotyping, FISH, and CMA OGM identified pathogenic variants in 12% of cases that altered ELN risk-level or identified eligibility for clinical trials OGM had 100%... Read More

A scientific workshop will feature Dr. Rashmi Kanagal-Shamanna from the University of Texas MD Anderson Cancer Center delivering a presentation on the use of emerging technologies for prognostication and research into myeloid neoplasms Four scientific posters featuring results from OGM applications in myeloid cancers, acute... Read More

Acquisition adds isotachophoresis (ITP), a proprietary technology licensed exclusively from Stanford University and developed by Purigen Biosystems for isolation and purification of nucleic acids, to the arsenal of tools for potentially simplifying ultra high molecular weight (UHMW) DNA isolation and purification for optical... Read More

SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study utilizing optical genome mapping (OGM) to detect structural variants (SVs) and balanced rearrangements relevant to prostate cancer (PCa) pathogenesis. OGM identified SVs in all samples, potentially improving the success rate for finding pathogenic variants and streamlining the detection process. In... Read More

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has appointed Donna Polizio as its global head of market access, further strengthening its leadership team. The appointment of a global head of market access reflects Bionano’s focus on advancing the adoption of optical genome mapping (OGM) and working to meet market needs. Ms. Polizio was most recently the vice... Read More

Dr. Alka Chaubey, chief medical officer at Bionano, Dr. Nikhil Sahajpal, Greenwood Genetic Center, Dr. Rashmi Kanagal-Shamanna, MD Anderson Cancer Center, and Dr. Adam Smith, University Health Network will host a sponsored vendor presentation on studies that include multiple types of hematological malignancies, and highlight the benefits of combining optical genome mapping (OGM) with next generation sequencing (NGS) to... Read More

Bionano Genomics, Inc. (BNGO) today announced that it will host a conference call and live webcast on Thursday, November 3, 2022 at 4:30 p.m. Eastern Time to report financial results for the third quarter 2022 and to highlight recent corporate progress. Conference Call & Webcast Details Date: Thursday, November 3, 2022 Time: 4:30 p.m. Eastern Time Live Call: Toll Free: 1-877-502-9276 Toll/International: 1-720-543-0302 Live... Read More

Hamilton and Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that the Long String VANTAGE, a system for automated, high throughput isolation of ultra high molecular weight (UHMW) DNA for use in optical genome mapping (OGM) is commercially available. The Long String VANTAGE is the result of collaborative development from the companies and features new and innovative tools and consumables used for consistent,... Read More

Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the company will host a “Meet the User” event today, October 24, 2022, at its new CLIA-certified Bionano Laboratories facility in advance of the American Society of Human Genetics (ASHG) Annual Meeting 2022. The event is the first scientific user meeting in the company’s history to bring together researchers curious about optical genome mapping (OGM) and experienced users,... Read More

Dr. Alka Chaubey, chief medical officer at Bionano, and Dr. Nikhil Sahajpal, fellow at Greenwood Genetic Center, will host a sponsored vendor presentation on a large clinical study utilizing optical genome mapping (OGM) for analysis of postnatal genetic disorders and the complementary use of OGM and next generation sequencing... Read More

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a peer-reviewed study evaluating optical genome mapping (OGM) as a method for investigating abnormal noninvasive prenatal testing (NIPT) results because of its ability to accurately identify complex structural aberrations relevant to recurrent pregnancy loss and infertility. In a case study from Hangzhou Maternity and Child Care Hospital, researchers... Read More

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation at the Spanish Society of Hematology (SEHH) 2022 Conference, with six scientific presentations from independent researchers covering a wide variety of the cancer genomics landscape, highlighting the application of optical genome mapping (OGM) for hematologic malignancies and cancer research. SEHH 2022 is a three-day conference dedicated to basic,... Read More

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study showing the use of optical genome mapping (OGM) to investigate a molecular subgroup of hepatocellular carcinoma (HCC), which is the most common form of liver cancer, in order to explore the complex structural variations (SVs) induced by replication stress. In this study, OGM helped unravel replication stress-induced events, which may cause or... Read More

Bionano Laboratories and OptraHEALTH today announced their collaboration to utilize HealthFAX’s proprietary AI platform to enhance genetic counseling services and improve care for patients receiving diagnostic services through the Bionano Laboratories. Bionano Laboratories utilizes cutting-edge technologies to provide genetic diagnostics in both clinical and research settings. Bionano Laboratories intends to scale its... Read More

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the launch of Bionano Laboratories, a new organization that combines Bionano’s optical genome mapping (OGM) data services with the clinical testing services previously offered by Lineagen, and the launch of Bionano Laboratories’ first OGM-based laboratory developed test (LDT). Bionano Laboratories recently received CLIA-certification for its lab in San Diego. This... Read More

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study utilizing OGM to detect cryptic balanced chromosomal rearrangements (BCRs) found in subjects who experienced recurrent pregnancy loss (RPL). Compared to traditional cytogenetic methods, OGM successfully identified cryptic reciprocal translocation in all samples, improving the success rate for finding pathogenic variants of cryptic BCRs and... Read More

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study evaluating the performance of OGM for detection of cytogenetic abnormalities in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) samples. This work is the second independent study, following a recent publication from researchers at MD Anderson Cancer Center, showing that OGM enables better molecular characterization of MDS. This... Read More

Bionano Genomics, Inc. (BNGO) announced today that company management will participate virtually at the H.C. Wainwright 24 th Annual Global Annual Global Investment Conference, taking place September 12-14, 2022. A pre-recorded presentation will be available on the Investor Resources page of the Company's website on Monday, September 12 at 7:00 am ET. About Bionano Genomics Bionano Genomics is a provider of genome analysis... Read More

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to use optical genome mapping (OGM) to analyze the impact of chromothripsis (cth) and TP53 abnormalities on chronic lymphocytic leukemia (CLL) patients with high genomic complexity. Researchers aimed to determine whether poor prognostic outcomes observed in cases with cth might be related not only to the chromothriptic event itself but... Read More

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to evaluate the utility of optical genome mapping (OGM) in the analysis of repeat expansion disorders. Repeat expansion disorders are a class of disorders that impact approximately 1 in 3,000 people and are caused by expansions of short tandem DNA repeats. Researchers in this study describe how OGM can be adopted as an alternative to... Read More

73% year-over-year revenue growth in Q2 2022 Achieved all 1H 2022 ELEVATE! milestones Strong balance sheet with $187.3 million in cash, cash equivalents, and available-for-sale securities at the end of Q2 2022 Conference call today, August 4th, 2022 at 4:30 PM ET Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome... Read More

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to evaluate the utility of optical genome mapping (OGM) for myelodysplastic syndrome (MDS) prognostication. In the peer-reviewed study, published in Leukemia , researchers from The University of Texas MD Anderson Cancer Center reported that when OGM was used instead of karyotyping, 17 to 21% of study subjects had different prognostic... Read More

Bionano Genomics, Inc. (BNGO) today announced that it will host a conference call and live webcast on Thursday, August 4th, 2022 at 4:30 p.m. Eastern Time to report financial results for the second quarter 2022 and to highlight recent corporate progress. Conference Call & Webcast Details Date: Thursday, August 4, 2022 Time: 4:30 p.m. Eastern Time Live Call: Register here for dial-in number and pin Live Webcast:... Read More

Dr. Alka Chaubey, chief medical officer at Bionano, will host a sponsored vendor panel presentation on the integration of optical genome mapping (OGM) and next generation sequencing (NGS) for clinical research in leukemia and lymphoma Four scientific platform presentations, one each by Dr. Ha Nguyen, MD Anderson Cancer Center, Dr. Adam Smith, University Health Network, Dr. Thuy Phung, University of South Alabama, and Dr.... Read More

Bionano Genomics, Inc. (Nasdaq: BNGO), today announced publication of a study using optical genome mapping (OGM) to investigate numerical and structural changes to two induced pluripotent stem cell (iPSC) lines, WTC-11 and Tuba1-GFP, during long-term culturing. This research provides scientific and practical support for the use of OGM workflows in regenerative medicine due to OGM’s ability to detect hundreds of structural... Read More

Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that the United States Patent and Trademark Office issued US Patent No.11,359,244 on June 14, 2022. The patent, titled “CHARACTERIZATION OF MOLECULES IN NANOFLUIDICS” claims methods for the analysis of small nucleic acid fragments in nanochannel arrays, which Bionano has traditionally used to analyze ultra-high molecular weight (UHMW) DNA for the identification of... Read More

Bionano will exhibit its solutions relevant to cancer research: the Saphyr ® system, NxClinical™ software and expert laboratory services A corporate satellite presentation by Alicia Bertolotti, Bionano, Dr. Sylvia Genovese, Bambino Gesù Children’s Hospital, and Dr. Juan Díaz-Martín, Institute of Biomedicine of Sevilla (IBiS), will cover the use of OGM for clinical research applications in solid tumor analysis 3 poster... Read More

The Long String VANTAGE for DNA isolation, a collaborative development between Bionano and Hamilton, and the world’s first automation solution for Ultra High Molecular Weight (UHMW) extraction used in optical genome mapping (OGM), will be on display at the conference A corporate satellite presentation by Dr. Detlef Trost, Laboratoire CERBA, and Dr. Alexander Hoischen, Radboud UMC, will cover the latest research on OGM for... Read More

Hamilton and Bionano Genomics, Inc . (Nasdaq: BNGO) today announced the collaborative development of the Long String VANTAGE for the isolation of Ultra High Molecular Weight (UHMW) DNA for use in optical genome mapping (OGM). Extraction of UHMW DNA of high quality and quantity is an important prerequisite and first step in Bionano’s sample preparation workflow. UHMW DNA extraction is generally performed manually by highly... Read More

Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the publication of a multi-platform study using OGM in combination with other cytogenetic technologies as a comprehensive strategy to investigate inversions that may lead to... Read More

Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced that researchers from University Health Network in Toronto, Columbia University Medical Center, and Children’s Hospital of Eastern Ontario will deliver a two-hour... Read More

Dr. Alka Chaubey, chief medical officer of Bionano, will present a spotlight session titled “OGM + NGS for Transforming Genome Biology: The Future is Bright!” Bionano is a Bronze Sponsor at the conference, and will host customers, KOLs and VIPs from the genomics, cytogenetics, and investment communities at an evening reception Conference attendees can experience the Saphyr system and view live demonstrations of Bionano’s... Read More

Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced that Glass Lewis & Co., a leading independent proxy advisory firm, has recommended that Bionano’s stockholders vote in favor of all proposals recommended by Bionano’s Board... Read More

Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the publication of the first peer-reviewed research study using optical genome mapping (OGM) to analyze genetic aberrations found in pediatric patients with acute myeloid... Read More

Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced its virtual participation in the 2022 H.C. Wainwright Global Investment Conference. Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present a company overview... Read More

For the first time at this conference, Bionano will exhibit all of its cytogenetic research solutions: OGM solutions, NxClinical software and laboratory services In a dedicated OGM scientific session, six presentations will illustrate the application of Bionano’s OGM in prenatal and postnatal testing, constitutional disease, and cancer Dr. Soheil Shams, chief informatics officer of Bionano, will present a scientific session... Read More

Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the publication of an evaluation of OGM from The First Affiliated Hospital of Zhengzhou, the largest hospital in Central China, highlighting the utility of OGM for structural... Read More

80% year-over-year revenue growth in Q1 2022 Achieved all Q1 2022 ELEVATE! milestones Strong balance sheet with $216.5 million in cash, cash equivalents, and available-for-sale securities at the end of Q1 2022 Conference call today, May 5th, 2022 at 4:30 PM ET Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of NxClinical™ software, a leading... Read More

Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced a peer-reviewed publication in Nature detailing the development of NeuroSCORE, a software-based method of analyzing complex genetic conditions that predicts and prioritizes... Read More

Bionano Genomics, Inc. (BNGO) today announced that it will host a conference call and live webcast on Thursday, May 5th, 2022 at 4:30 p.m. Eastern Time to report financial results for the first quarter 2022 and to highlight recent corporate progress. Conference Call & Webcast Details Date: Thursday, May 5, 2022 Time: 4:30 p.m. Eastern Time Toll Free: 1-800-239-9838 International: 1-720-543-0214 Conference ID: 2258678... Read More

Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced that the United States Patent and Trademark Office issued two new US Patents, No. 11,291,999 and No. 11,292,713 on April 5, 2022. The ‘999 patent, titled “Photocleavage... Read More

Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the launch of an integrated genomic scar analysis for homologous recombination deficiency (HRD) in the version 6.2 software release of N x Clinical. This feature provides a... Read More

Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the publication of a new study using OGM in combination with multiple other cytogenetic methods and a new single-cell analysis method as a comprehensive molecular strategy to... Read More

Bionano will exhibit all of its solutions relevant to cancer research: OGM systems, NxClinical software and expert laboratory services Exhibitor Theater presentation will share the latest OGM research on comprehensive genomic structural variation and homologous recombination deficiency (HRD) analysis from tumor biopsies Three scientific poster presentations will illustrate the application of Bionano’s OGM in hematological... Read More

SAN DIEGO, March 25, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO ), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the final speaker lineup for its 2022 China Symposium. The Symposium will be held March 26, 2022, and features 9 presentations... Read More

SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, announced today that company management will present at the 2022 Maxim Virtual Growth Conference. Erik Holmlin, PhD, Bionano’s president and chief... Read More

Bionano is back in-person at the ACMG annual meeting – this time as ONE COMPANY with MORE SOLUTIONS For the first time, Bionano will exhibit all of its products and solutions with its combined commercial teams together [in one location] Optical Genome Mapping Solutions, Testing and Laboratory Services, & Software Six scientific posters will illustrate the capabilities and scope of Bionano’s solutions for impacting clinical... Read More

Key findings from evaluation of 59 Heme Samples and 10 Controls: OGM detected 162/164 SVs detected by standard cytogenetics methods of karyotyping and FISH OGM detected chromosomal aberrations missed by karyotyping and FISH in 35 cases OGM Sensitivity: 98.7% OGM Specificity: 100% Positive Predictive Value: 100% Negative Predictive Value: 98% OGM Accuracy: 99.2% First-Pass Success Rate: 100% Limit of Detection (LOD) for... Read More

Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™, a leading software solution for visualization, interpretation, and reporting of genomic data, announced today that company management will present virtually at the 32 nd Annual Oppenheimer Healthcare Conference. Erik Holmlin, PhD, Bionano’s president and chief executive officer, is scheduled... Read More